

LIFE SCIENCES

Clinical Trial Research Centers in Peru

STATISTICS – FEBRUARY 2026



1. REGULATORY OVERVIEW AND KEY DATA ON THE NETWORK OF AUTHORIZED RESEARCH CENTERS IN PERU


The development of clinical trials in Peru requires that each study be conducted at a research center registered in the Peruvian Registry of Clinical Trials (REPEC) and that it complies with the requirements of the Clinical Trials Regulation (Supreme Decree No. 021-2017-SA and its amendment).

A *research center* is defined as the physical unit of the institution where one or more clinical trials are conducted, in compliance with the conditions set forth in Annex 3 of the Regulations.

As of February 2026, REPEC has registered:



263
RESEARCH
CENTERS




5,088
CUMULATIVE
AUTHORIZED
CLINICAL TRIALS

2. NATIONAL OVERVIEW OF RESEARCH CENTERS*

The following table presents the national situation of research centers registered with REPEC, showing their distribution according to operational status. The review showed that, of the 217 active centers, 29 do not register authorized clinical trials (CT) (13.4%), revealing underutilized installed capacity. Likewise, 12 centers (4.6%) are inactive for new clinical trials, a condition that requires regularization before they can participate in new studies again, constituting a critical point of attention for sponsors and CROs when planning site selection.

Distribution of research centers by state (REPEC)




EC authorized by center state		
	Situation	Cumulative EC
	Active	4,560
	Cancelled	278
	Inactive for new clinical trials	232
	Suspended for safety reasons	18

SOURCE: REPEC EXCEL FILE. LAST ENTRY 02/21/2026.

3. TOP 5 CENTERS BY NUMBER OF AUTHORIZED CLINICAL TRIALS*

The following analysis summarizes the 5 centers with the highest historical activity in clinical research in Peru, measured by the total number of authorized clinical trials accumulated. The top two places correspond to institutions specializing in oncology, with the National Institute of Neoplastic Diseases (INEN) in first place, a public entity of the Ministry of Health (MINSA) focused on the comprehensive management of neoplastic diseases.

Top 5 centers by number of authorized clinical trials



SOURCE: REPEC-INS (FILE 02/21/2026) OWN ELABORATION

* SOURCE: REPEC EXCEL FILE. LAST ENTRY 02/21/2026.

4. CONCLUSIONS

Peru has

263

authorized research centers, which shows that there is a wide network of institutions to conduct clinical trials in the country.

Of the total,

217

centers are active (82.5%); however, 29 of them do not register authorized clinical trials (13.4%), which shows underutilized installed capacity that could be leveraged through strategies to strengthen and develop new sites.

An analysis of the

TOP 5

most active centers shows that the top two spots are occupied by institutions specializing in oncology, with the National Institute of Neoplastic Diseases (INEN) in first place. This result indicates that a significant proportion of national clinical research is focused on oncological diseases.

For more information,
please contact our team:



MARITZA REÁTEGUI

PARTNER

MREATEGUI@ESTUDIORODRIGO.COM



CECILIA ALARCÓN

CONSULTANT

CALARCON@ESTUDIORODRIGO.COM



PAUL MIYASHIRO

CONSULTANT

PMIYASHIRO@ESTUDIORODRIGO.COM



SOLANGE NORIEGA

ASSOCIATE

SNORIEGA@ESTUDIORODRIGO.COM